Azitra, Inc. (AZTR): R&D Expense

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2023-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$4.84M

Year ended 2025-12-31

$5.10M

Trailing 12 months to 2026-06-30

2022-12-31 R&D Expense (USD) 2025-12-31

Period ended	R&D Expense	Change YoY	Source filing
2025-12-31	$4.84M	+2.4%	2026-02-27, From 2025-01-01
2024-12-31	$4.72M	+29.6%	2026-02-27, From 2024-01-01
2023-12-31	$3.64M	n/c	2025-02-24, From 2023-01-01
2022-12-31	$6.10M	n/a	2024-03-15, From 2022-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	R&D Expense	Change YoY
Azitra, Inc. (AZTR)	2025-12-31	$4.84M	+2.4%
Abbott Laboratories (ABT)	2025-12-31	$2.94B	+3.4%
Bristol Myers Squibb Co (BMY)	2025-12-31	$9.95B	-10.8%
Eli Lilly & Co (LLY)	2025-12-31	$13.34B	+21.3%
Pfizer Inc (PFE)	2025-12-31	$10.44B	-3.6%
Johnson & Johnson (JNJ)	2025-12-28	$14.66B	-14.9%
Nature's Sunshine Products Inc (NATR)	2025-12-31	$1.90M	+11.8%
Merck & Co., Inc. (MRK)	2025-12-31	$15.79B	-12.0%
Provectus Biopharmaceuticals, Inc. (PVCT)	2025-12-31	$1.90M	-7.5%

Compare AZTR, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗